Joint Commission Issues Sentinel Alert for Safe Opioid Use
Opioid analgesics rank among the drugs most frequently associated with adverse drug events. Opioids such as morphine, oxycodone and methadone can cause serious complications, including slow breathing to dangerous levels, and even death. The reasons for such adverse events include dosing errors, improper monitoring of patients and interactions with other drugs.
The Joint Commission recommends that healthcare organizations take the following actions:
• Implement effective practices, such as monitoring patients who are receiving opioids on an ongoing basis, use pain management specialists or pharmacists to review pain management plans, and track opioid incidents.
• Use available technology to improve prescribing safety of opioids such as creating alerts for dosing limits, using tall man lettering in electronic ordering systems, using a conversion support system to calculate correct dosages and using patient-controlled analgesia.
• Provide education and training for clinicians, staff and patients about the safe use of opioids.
• Use standardized tools to screen patients for risk factors such as oversedation and respiratory depression.
More Articles on The Joint Commission:
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- GI leader to know: Dr. Paramvir Rahal of the Institute of Advanced Gastroenterology
- SurgCenter Development ASCs perform almost 7k joint replacements in 2016; NY Department of Health approves Frontier, Liberty Endoscopy Center's ASC plans & more — 5 ASC company notes
- Participants race to increase colon cancer awareness during 2017 Greater Chattanooga Rump Run 5K and Fun Walk: 4 takeaways
- US woman dies from superbug resistant to 26 antibiotics — 8 things to know
- Healthcare nanotechnology market to grow at a CAGR above 12% till 2024